New cancer drug combination significantly delays breast cancer progression, phase II study shows
Sunday, September 25, 2011 - 20:30
in Health & Medicine
The first randomised trial to investigate the use of trastuzumab emtansine (T-DM1) for the initial treatment of HER2 positive metastatic breast cancer has shown that it makes a significant difference to the time women live without their disease worsening. Patients with the cancer who received T-DM1 had a 41 percent improvement in the time they lived without it worsening compared to those who received standard docetaxel chemotherapy plus trastuzumab.